Why the study?
Do specific tyrosine kinase inhibitors alter circulating biomarkers of endothelial dysfunction and hs-CRP in patients with chronic myeloid leukemia?
Do specific tyrosine kinase inhibitors alter circulating biomarkers of endothelial dysfunction and hs-CRP in patients with chronic myeloid leukemia?
Circulating markers of vascular dysfunction are altered in CML patients treated with specific TKIs (such as nilotinib and ponatinib) and may serve as potential markers for TKI-associated cardiovascular risk.
Endothelial markers may flag TKI-specific vascular risk in CML; leaves open predictive value and practice change.
= 0.024) were independently associated with higher hs-CRP. In exploratory analyses, novel endothelial-centric markers (e.g. ET-1 and VCAM-1) were differential across the various TKIs, particularly amongst nilotinib- and ponatinib-treated patients. While Levels of hs-CRP do not appear to be correlated with specific TKIs, circulating markers of vascular dysfunction were altered in patients treated with specific TKIs and should be explored as potential markers of TKI-associated CV risk.
No takes yet. Share an insight, caveat, or question.
Aghel et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: